Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.

Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM, Gale M Jr.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):6001-6. Epub 2006 Apr 3.

2.

Functional and therapeutic analysis of hepatitis C virus NS3.4A protease control of antiviral immune defense.

Johnson CL, Owen DM, Gale M Jr.

J Biol Chem. 2007 Apr 6;282(14):10792-803. Epub 2007 Feb 8.

3.

GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS.

Chen Z, Benureau Y, Rijnbrand R, Yi J, Wang T, Warter L, Lanford RE, Weinman SA, Lemon SM, Martin A, Li K.

J Virol. 2007 Jan;81(2):964-76. Epub 2006 Nov 8.

4.

Recruitment of an interferon molecular signaling complex to the mitochondrial membrane: disruption by hepatitis C virus NS3-4A protease.

Hiscott J, Lacoste J, Lin R.

Biochem Pharmacol. 2006 Nov 30;72(11):1477-84. Epub 2006 Jul 31.

PMID:
16876765
5.

Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.

Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD.

Antimicrob Agents Chemother. 2013 Sep;57(9):4417-26. doi: 10.1128/AAC.00399-13. Epub 2013 Jul 8.

6.

Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms.

Cheng G, Zhong J, Chisari FV.

Proc Natl Acad Sci U S A. 2006 May 30;103(22):8499-504. Epub 2006 May 17.

7.

Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway.

Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, Lin R, Hiscott J.

Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):17-28.

PMID:
16914100
8.

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Ahlén G, Derk E, Weiland M, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grandér D, Frelin L, Sällberg M.

Gut. 2009 Apr;58(4):560-9. doi: 10.1136/gut.2007.147264. Epub 2008 Aug 8.

9.

Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus.

Mibayashi M, Martínez-Sobrido L, Loo YM, Cárdenas WB, Gale M Jr, García-Sastre A.

J Virol. 2007 Jan;81(2):514-24. Epub 2006 Nov 1.

10.
11.

Hepatitis C virus proteins interfere with the activation of chemokine gene promoters and downregulate chemokine gene expression.

Sillanpää M, Kaukinen P, Melén K, Julkunen I.

J Gen Virol. 2008 Feb;89(Pt 2):432-43. doi: 10.1099/vir.0.83316-0.

PMID:
18198374
12.

Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression.

Kaukinen P, Sillanpää M, Kotenko S, Lin R, Hiscott J, Melén K, Julkunen I.

Virol J. 2006 Sep 1;3:66.

13.

Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7.

Daffis S, Suthar MS, Szretter KJ, Gale M Jr, Diamond MS.

PLoS Pathog. 2009 Oct;5(10):e1000607. doi: 10.1371/journal.ppat.1000607. Epub 2009 Oct 2.

14.

Hepatitis C virus controls interferon production through PKR activation.

Arnaud N, Dabo S, Maillard P, Budkowska A, Kalliampakou KI, Mavromara P, Garcin D, Hugon J, Gatignol A, Akazawa D, Wakita T, Meurs EF.

PLoS One. 2010 May 11;5(5):e10575. doi: 10.1371/journal.pone.0010575.

15.

Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity.

Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M.

Hepatology. 2013 Jan;57(1):46-58. doi: 10.1002/hep.26017.

PMID:
22911572
16.

Hepatitis C virus reveals a novel early control in acute immune response.

Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, Wakita T, Meurs EF.

PLoS Pathog. 2011 Oct;7(10):e1002289. doi: 10.1371/journal.ppat.1002289. Epub 2011 Oct 13.

17.

DEAD/H BOX 3 (DDX3) helicase binds the RIG-I adaptor IPS-1 to up-regulate IFN-beta-inducing potential.

Oshiumi H, Sakai K, Matsumoto M, Seya T.

Eur J Immunol. 2010 Apr;40(4):940-8. doi: 10.1002/eji.200940203.

18.

A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.

Franco S, Clotet B, Martínez MA.

Virus Res. 2008 Feb;131(2):260-70. Epub 2007 Nov 26.

PMID:
18037183
19.

Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.

Liang Y, Ishida H, Lenz O, Lin TI, Nyanguile O, Simmen K, Pyles RB, Bourne N, Yi M, Li K, Lemon SM.

Gastroenterology. 2008 Nov;135(5):1710-1718.e2. doi: 10.1053/j.gastro.2008.07.023. Epub 2008 Jul 22.

PMID:
18725224
20.

Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1.

Zekri AR, Moharram RA, Mohamed WS, Bahnassy AA, Alam El-Din HM, Abo-Shadi MM, Zayed NA, El-Magzangy H, Abdel-Aziz AO, Esmat G.

Eur J Gastroenterol Hepatol. 2010 Apr;22(4):450-6. doi: 10.1097/MEG.0b013e3283329d00.

PMID:
19858727
Items per page

Supplemental Content

Write to the Help Desk